Current status of adjuvant chemotherapy for gastric cancer

被引：0

作者：

In-Hwan Kim ^{[1
]}

机构：

[1] Department of Surgery, Catholic University of Daegu

来源：

World Journal of Gastrointestinal Oncology | 2019年 / 09期

关键词：

Gastric cancer; Adjuvant chemotherapy; Perioperative chemotherapy; Chemoradiotherapy; Guidelines;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤]; R730.53 [化学（药物）疗法];

学科分类号：

100214 ;

摘要：

Although radical gastrectomy is a standard treatment for advanced gastric cancer, recurrence remains high. After several large-scale controlled studies have shown the beneficial effects of adjuvant chemotherapy, that treatment emerged as a standard option for advanced gastric cancer after gastrectomy. However,various guidelines from different countries have suggested different adjuvant chemotherapies. Understanding the differences between guidelines is very important for investigating further therapeutic strategies. Fortunately, because there are many ongoing studies about new regimens for adjuvant treatment, it is expected that patients with gastric cancer after surgery will have better outcome.

引用

页码：679 / 685

页数：7

共 16 条

[1] Adjuvant therapy for locally advanced gastric cancer [J].

Aoyama, Toru ;

Yoshikawa, Takaki .

SURGERY TODAY, 2017, 47 (11) :1295-1302

[2]

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial[J] . David Cunningham,Sally P Stenning,Elizabeth C Smyth,Alicia F Okines,William H Allum,Sam Rowley,Laura Stevenson,Heike I Grabsch,Derek Alderson,Thomas Crosby,S Michael Griffin,Wasat Mansoor,Fareeda Y Coxon,Stephen J Falk,Suzanne Darby,Kate A Sumpter,Jane M Blazeby,Ruth E Langley

[3] Mechanisms of Resistance to Chemotherapy in Gastric Cancer [J].

Marin, J. J. G. ;

Al-Abdulla, R. ;

Lozano, E. ;

Briz, O. ;

Bujanda, L. ;

Banales, J. M. ;

Macias, R. I. R. .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2016, 16 (03) :318-334

[4]

East Versus West[J] . Tomio Ueno,Michihisa Iida,Shigefumi Yoshino,Shigeru Takeda,Toshiko Kubota,Masaharu Higashida,Yasuo Oka,Atushi Tsuruta,Hideo Matsumoto,Hiroaki Nagano.Surgical Clinics of North America . 2016

[5]

Global cancer statistics, 2012[J] . Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal.CA: A Cancer Journal for Clinicians . 2015 (2)

[6]

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial[J] . Sung Hoon Noh,Sook Ryun Park,Han-Kwang Yang,Hyun Cheol Chung,Ik-Joo Chung,Sang-Woon Kim,Hyung-Ho Kim,Jin-Hyuk Choi,Hoon-Kyo Kim,Wansik Yu,Jong Inn Lee,Dong Bok Shin,Jiafu Ji,Jen-Shi Chen,Yunni Lim,Stella Ha,Yung-Jue Bang.Lancet Oncology . 2014 (12)

[7] The Prognostic Significance of an R1 Resection in Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy [J].

Stiekema, Jurrien ;

Trip, Anouk K. ;

Jansen, Edwin P. M. ;

Boot, Henk ;

Cats, Annemieke ;

Ponz, Olga Balague ;

Verheij, Marcel ;

van Sandick, Johanna W. .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (04) :1107-1114

[8]

Cancer statistics, 2013[J] . Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.CA: A Cancer Journal for Clinicians . 2013 (1)

[9]

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J] . Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun-Wook Lee,Yong Ho Kim,Sang-Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta-Sen Yeh,Peter Button,Florin Sirzén,Sung Hoon Noh.The Lancet . 2012 (9813)

[10]

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J] . Ilfet Songun,Hein Putter,Elma Meershoek-Klein Kranenbarg,Mitsuru Sasako,Cornelis JH van de Velde.Lancet Oncology . 2010 (5)

← 1 2 →